AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.
AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.
10/22/24, 10:21 AM
Location
cambridgeMoney raised
$112 million
Industry
therapeutics
medical
biotechnology
health care
Round Type
series b
Investors
Blackstone Life Sciences, Nybc Ventures, Piper Heartland Healthcare Capital, Eight Roads Ventures Japan, F Prime Capital, Novo Holdings
AvenCell Therapeutics, Inc. has successfully raised $112 million in its Series B financing round. The funding, led by Novo Holdings and joined by new investors such as F-Prime Capital and Eight Roads Ventures Japan, will support the clinical development of its innovative CAR-T cell therapy platform.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies. Their proprietary Universal Switchable CAR-T cell therapy platform is designed to treat various hematologic malignancies and autoimmune diseases. AvenCell aims to transform the standard of care with innovative and adaptable cell therapy treatments. The company has several pipeline candidates in clinical trials addressing high unmet medical needs.